Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 17.42 EUR 1.52% Market Closed
Market Cap: 509.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Relative Value

The Relative Value of one MEDCL stock under the Base Case scenario is 8.51 EUR. Compared to the current market price of 17.42 EUR, Medincell SA is Overvalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEDCL Relative Value
Base Case
8.51 EUR
Overvaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
6
Median 3Y
25
Median 5Y
32.6
Industry
2.5
Forward
15.6
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
21.9
Forward
-48.1
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-11.4
Industry
16.5
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-14
Industry
23.6
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.1
Industry
2.1
vs History
28
vs Industry
6
Median 3Y
26.4
Median 5Y
31.5
Industry
2.6
Forward
16.6
vs History
30
vs Industry
3
Median 3Y
35.6
Median 5Y
46.4
Industry
5.2
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-10.6
Industry
13.3
Forward
115.2
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.9
Industry
16.6
Forward
1 183.3
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-12.5
Industry
15.6
vs History
vs Industry
Median 3Y
-10
Median 5Y
-11.9
Industry
19.1
vs History
3
vs Industry
6
Median 3Y
12.9
Median 5Y
14
Industry
1.9

Multiples Across Competitors

MEDCL Competitors Multiples
Medincell SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Medincell SA
PAR:MEDCL
506.4m EUR 56.1 -20.2 -28.2 -25.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
FR
Medincell SA
PAR:MEDCL
Average P/E: 32.4
Negative Multiple: -20.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
EV/EBITDA Multiple
EBITDA Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBITDA: 484.8
Negative Multiple: -28.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A
US
Eli Lilly and Co
NYSE:LLY
45.7
195%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
DK
Novo Nordisk A/S
CSE:NOVO B
24.3
84%
US
Johnson & Johnson
NYSE:JNJ
12.3
14%
US
Merck & Co Inc
NYSE:MRK
10.5
331%
CH
Roche Holding AG
SIX:ROG
9.9
23%
CH
Novartis AG
SIX:NOVN
10.1
8%
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
IE
E
Endo International PLC
LSE:0Y5F
234.4
N/A

See Also

Discover More
Back to Top